Table 1.
Demographics and baseline clinical characteristics
| Overall (n=203) | No Recurrence (n=180) | Recurrence (n=23) | P-value | |
|---|---|---|---|---|
| Median age at diagnosis (IQR) | 60 (52–71) | 60 (52–72) | 59 (52.5–63.5) | 0.42 |
| No. gender (%) | ||||
| Male | 132 (65) | 115 (63.9) | 17 (73.9) | 0.49 |
| Female | 71 (35) | 65 (36.1) | 6 (26.1) | |
| No. race (%) | ||||
| White | 160 (78.8) | 143 (79.4) | 17 (73.9) | 0.67 |
| Black | 3 (1.5) | 3 (1.7) | 0 (0) | |
| Asian | 2 (1) | 2 (1.1) | 0 (0) | |
| Unavailable | 38 (18.7) | 32 (17.8) | 6 (26.1) | |
| No. primary tumor laterality (%) | ||||
| Right | 111 (54.7) | 100 (55.6) | 11 (47.8) | 0.13 |
| Left | 83 (40.9) | 74 (41.1) | 9 (39.1) | |
| Unavailable | 9 (4.4) | 6 (3.3) | 3 (13) | |
| No. primary tumor grade (%) | ||||
| G1 | 12 (5.9) | 12 (6.7) | 0 (0) | 0.02 |
| G2 | 131 (64.5) | 121 (67.2) | 10 (43.5) | |
| G3 | 55 (27.1) | 43 (23.9) | 12 (52.2) | |
| G4 | 5 (2.5) | 4 (2.2) | 1 (4.3) | |
| No. T stage (%) | ||||
| T1 | 179 (88.2) | 162 (90) | 17 (73.9) | 0.05 |
| T3a | 10 (4.9) | 8 (4.4) | 2 (8.7) | |
| T3b | 6 (3) | 5 (2.8) | 1 (4.3) | |
| Unavailable | 8 (3.9) | 5 (2.8) | 3 (13) | |
| No. N stage (%) | ||||
| N0 | 82 (40.4) | 75 (41.7) | 7 (30.4) | 0.02 |
| N1 | 1 (0.5) | 1 (0.6) | 0 (0) | |
| N2 | 1 (0.5) | 0 (0) | 1 (4.3) | |
| NX | 111 (54.7) | 99 (55) | 12 (52.2) | |
| Unavailable | 8 (3.9) | 5 (2.8) | 3 (13) | |
| No. M stage (%) | 0.0005 | |||
| M0 | 150 (73.9) | 142 (78.9) | 8 (34.8) | |
| M1 | 11 (5.4) | 3 (1.7) | 8 (34.8) | |
| MX | 34 (16.8) | 30 (16.7) | 4 (17.4) | |
| Unavailable | 8 (3.9) | 5 (2.8) | 3 (13) | |
| No. AJCC stage (%) | 0.0005 | |||
| Stage I | 177 (87.2) | 164 (91.1) | 13 (56.5) | |
| Stage III | 13 (6.4) | 13 (7.2) | 0 (0) | |
| Stage IV | 13 (6.4) | 3 (1.7) | 10 (43.5) |